Literature DB >> 28736274

Biomarkers as a treatment guide in rheumatoid arthritis.

Tsutomu Takeuchi1.   

Abstract

It is anticipated that biomarkers support rheumatologists to judge a group of patients that can improve the diagnosis and prognosis, and further facilitate appropriate and precise treatment with targeted therapy. In particular, biomarkers for predicting and monitoring response to biological disease modifying anti-rheumatic drugs (DMARDs) are demanding. Given the mechanism action of biological DMARDs is much more simple than the conventional synthetic DMARDs, a variety of approaches to find such biomarkers has been taken recent years. In this article, I will summarize the background for biomarker research and introduce recent topics in the research and the possible clinical applications of biomarkers to guide treatment in rheumatoid arthritis (RA).
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biological agents; Biologics; Cytokine; Drug level; Treatment; bDMARDs

Mesh:

Substances:

Year:  2017        PMID: 28736274     DOI: 10.1016/j.clim.2017.07.019

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

Review 1.  Potential clinical biomarkers in rheumatoid arthritis with an omic approach.

Authors:  Yolima Puentes-Osorio; Pedro Amariles; Miguel Ángel Calleja; Vicente Merino; Juan Camilo Díaz-Coronado; Daniel Taborda
Journal:  Auto Immun Highlights       Date:  2021-05-31

Review 2.  Electrochemical Biosensors as Potential Diagnostic Devices for Autoimmune Diseases.

Authors:  Anca Florea; Gheorghe Melinte; Ioan Simon; Cecilia Cristea
Journal:  Biosensors (Basel)       Date:  2019-03-04

Review 3.  DNA Methylation as a Future Therapeutic and Diagnostic Target in Rheumatoid Arthritis.

Authors:  Marzena Ciechomska; Leszek Roszkowski; Wlodzimierz Maslinski
Journal:  Cells       Date:  2019-08-22       Impact factor: 6.600

4.  Impact of autoimmune serology test results on RA classification and diagnosis.

Authors:  Lieve Van Hoovels; Paul Studenic; Daniela Sieghart; Günter Steiner; Xavier Bossuyt; Johan Rönnelid
Journal:  J Transl Autoimmun       Date:  2022-01-06

5.  Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis.

Authors:  Borja Hernández-Breijo; Ioannis Parodis; Marta Novella-Navarro; Ana Martínez-Feito; Victoria Navarro-Compán; Mariana Díaz-Almirón; Dora Pascual-Salcedo; Alejandro Balsa; Chamaida Plasencia-Rodríguez
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

6.  Standardisation of ACPA tests: evaluation of a new candidate reference preparation.

Authors:  Lieve Van Hoovels; Lucy Studholme; Bert Vander Cruyssen; Daniela Sieghart; Carolien Bonroy; Eszter Nagy; Rille Pullerits; Sasa Čučnik; Charlotte Dahle; Ingmar Heijnen; Luca Bernasconi; Farid Benkhadra; Laura Bogaert; Stefanie Van Den Bremt; Ann Van Liedekerke; Geert Vanheule; Johan Robbrecht; Claudine Wirth; Rüdiger Müller; Diego Kyburz; Christopher Sjöwall; Alf Kastbom; Rok Ješe; Boja Jovancevic; Emese Kiss; Peggy Jacques; Daniel Aletaha; Günter Steiner; Patrick Verschueren; Xavier Bossuyt
Journal:  Ann Rheum Dis       Date:  2022-06-13       Impact factor: 27.973

Review 7.  Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease.

Authors:  Tsutomu Takeuchi
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2017       Impact factor: 3.493

Review 8.  Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review.

Authors:  Hanna Gul; Kate Harnden; Benazir Saleem
Journal:  Healthcare (Basel)       Date:  2021-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.